Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors

NCT00298675 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
59
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi